{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:54:21Z","timestamp":1792086861467,"version":"4.4.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIDDK K08 DK110332"],"award-info":[{"award-number":["NIDDK K08 DK110332"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.coph.2020.06.001","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T07:15:14Z","timestamp":1594797314000},"page":"11-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Evolving understanding of cardiovascular protection by SGLT2 inhibitors: focus on renal protection, myocardial effects, uric acid, and magnesium balance"],"prefix":"10.1016","volume":"54","author":[{"given":"Evan C","family":"Ray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2020.06.001_bib0005","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","article-title":"Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus","volume":"75","author":"Scheen","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.coph.2020.06.001_bib0010","series-title":"Guidance for industry. Diabetes Mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes","author":"U.S. Food and Drug Administration","year":"2008"},{"key":"10.1016\/j.coph.2020.06.001_bib0015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2020.06.001_sbref0020","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2020.06.001_sbref0025","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in Type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2020.06.001_sbref0030","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in Type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2020.06.001_sbref0035","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in Type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2020.06.001_sbref0040","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2020.06.001_sbref0045","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in Type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2020.06.001_bib0050","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/dom.12670","article-title":"Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis","volume":"18","author":"Zaccardi","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.coph.2020.06.001_bib0055","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1177\/1060028019859323","article-title":"Sodium-glucose cotransporters as potential therapeutic targets in patients with Type 1 diabetes mellitus: an update on Phase 3 clinical trial data","volume":"53","author":"Patel","year":"2019","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.coph.2020.06.001_bib0060","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/MED.0b013e3283446b7e","article-title":"Glycemic control and cardiovascular mortality","volume":"18","author":"Riddle","year":"2011","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.coph.2020.06.001_bib0065","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1007\/s00125-009-1470-0","article-title":"Intensive glucose control and macrovascular outcomes in type 2 diabetes","volume":"52","author":"Turnbull","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.coph.2020.06.001_bib0070","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/jcph.1030","article-title":"Model-based evaluation of proximal sodium reabsorption through SGLT2 in health and diabetes and the effect of inhibition with canagliflozin","volume":"58","author":"Brady","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.coph.2020.06.001_bib0075","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12933-019-0852-y","article-title":"Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy","volume":"18","author":"Schork","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.coph.2020.06.001_bib0080","article-title":"WITHDRAWN: diuretics for heart failure","volume":"4","author":"Faris","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.coph.2020.06.001_bib0085","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s10741-019-09771-8","article-title":"READY: relative efficacy of loop diuretics in patients with chronic systolic heart failure-a systematic review and network meta-analysis of randomised trials","volume":"24","author":"Tager","year":"2019","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.coph.2020.06.001_bib0090","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/ajh\/hpv050","article-title":"Cardioprotective effect of thiazide-like diuretics: a meta-analysis","volume":"28","author":"Chen","year":"2015","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.coph.2020.06.001_sbref0095","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/dom.13670","article-title":"Uric acid and the cardio-renal effects of SGLT2 inhibitors","volume":"21","author":"Bailey","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.coph.2020.06.001_bib0100","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/dom.13101","article-title":"Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials","volume":"20","author":"Zhao","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.coph.2020.06.001_bib0105","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/eurjhf\/hft132","article-title":"Uric acid and risk of heart failure: a systematic review and meta-analysis","volume":"16","author":"Huang","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.coph.2020.06.001_bib0110","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijcard.2017.05.032","article-title":"Sodium-dependent glucose transporters (SGLT) in human ischemic heart: a new potential pharmacological target","volume":"243","author":"Di Franco","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.coph.2020.06.001_bib0115","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/jdi.12214","article-title":"Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: clinical data and mechanism of action","volume":"5","author":"Fujita","year":"2014","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.coph.2020.06.001_bib0120","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20133289","article-title":"Inhibition of sodium glucose cotransporters improves cardiac performance","volume":"20","author":"Garc\u00eda-Ropero","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coph.2020.06.001_bib0125","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11010-014-2262-5","article-title":"Dapagliflozin reduces the amplitude of shortening and Ca2+ transient in ventricular myocytes from streptozotocin-induced diabetic rats","volume":"400","author":"Hamouda","year":"2015","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.coph.2020.06.001_bib0130","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+\/H+ exchanger in rats and rabbits","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.coph.2020.06.001_bib0135","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2017.01077","article-title":"Empagliflozin limits myocardial infarction in vivo and cell death in vitro: role of STAT3, mitochondria, and redox aspects","volume":"8","author":"Andreadou","year":"2017","journal-title":"Front Physiol"},{"key":"10.1016\/j.coph.2020.06.001_bib0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2020.165770","article-title":"SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models","volume":"1866","author":"Andreadou","year":"2020","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.coph.2020.06.001_bib0145","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coph.2020.06.001_bib0150","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10557-008-6083-1","article-title":"Metabolic (in)flexibility of the diabetic heart","volume":"22","author":"Larsen","year":"2008","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.coph.2020.06.001_bib0155","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.nefro.2015.05.025","article-title":"Risk of mortality associated to chronic kidney disease in patients with type 2 diabetes mellitus: a 13-year follow-up","volume":"35","author":"Gimeno-Orna","year":"2015","journal-title":"Nefrologia"},{"key":"10.1016\/j.coph.2020.06.001_bib0160","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.ekir.2018.06.007","article-title":"Urinary Plasmin(ogen) as a prognostic factor for hypertension","volume":"3","author":"Ray","year":"2018","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.coph.2020.06.001_bib0165","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S2213-8587(17)30182-1","article-title":"Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial","volume":"5","author":"Cherney","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.coph.2020.06.001_bib0170","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/978-981-13-8871-2_24","article-title":"New understanding on the role of proteinuria in progression of chronic kidney disease","volume":"1165","author":"Liu","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.coph.2020.06.001_bib0175","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1053\/j.ackd.2014.11.006","article-title":"Sodium retention and volume expansion in nephrotic syndrome: implications for hypertension","volume":"22","author":"Ray","year":"2015","journal-title":"Adv Chron Kidney Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.coph.2020.06.001_sbref0180","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.amjcard.2019.10.027","article-title":"Renal effects of sodium-glucose co-transporter inhibitors","volume":"124","author":"Thomson","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.coph.2020.06.001_sbref0185","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","article-title":"The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial","volume":"97","author":"van Bommel","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.coph.2020.06.001_bib0190","doi-asserted-by":"crossref","first-page":"366","DOI":"10.2215\/CJN.02960906","article-title":"Hypomagnesemia in patients with type 2 diabetes","volume":"2","author":"Pham","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.coph.2020.06.001_bib0195","series-title":"Usual Nutrient Intakes From Food And Water Compared to 1997 Dietary Reference Intakes for Vitamin D, Calcium, Phosphorus, and Magnesium","article-title":"What we eat in America, NHANES 2005\u20132006","author":"Moshfegh","year":"2009"},{"key":"10.1016\/j.coph.2020.06.001_sbref0200","doi-asserted-by":"crossref","first-page":"7192","DOI":"10.1096\/fj.201801778RR","article-title":"Renal phospholipidosis and impaired magnesium handling in high-fat-diet-fed mice","volume":"33","author":"Kurstjens","year":"2019","journal-title":"FASEB J"},{"key":"10.1016\/j.coph.2020.06.001_bib0205","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1172\/JCI107690","article-title":"The effect of glucose on urinary cation excretion during chronic extracellular volume expansion in normal man","volume":"53","author":"Lennon","year":"1974","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coph.2020.06.001_bib0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/CS20120045","article-title":"Drug-induced alterations in Mg2+ homoeostasis","volume":"123","author":"Lameris","year":"2012","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.coph.2020.06.001_bib0215","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1093\/clinchem\/33.11.1965","article-title":"Assessment of magnesium status","volume":"33","author":"Elin","year":"1987","journal-title":"Clin Chem"},{"key":"10.1016\/j.coph.2020.06.001_sbref0220","first-page":"S194","article-title":"Assessment of magnesium status for diagnosis and therapy","volume":"23","author":"Elin","year":"2010","journal-title":"Magnes Res"},{"key":"10.1016\/j.coph.2020.06.001_bib0225","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s12916-016-0742-z","article-title":"Dietary magnesium intake and the risk of cardiovascular disease, type 2 diabetes, and all-cause mortality: a dose-response meta-analysis of prospective cohort studies","volume":"14","author":"Fang","year":"2016","journal-title":"BMC Med"},{"key":"10.1016\/j.coph.2020.06.001_bib0230","doi-asserted-by":"crossref","first-page":"e5406","DOI":"10.1097\/MD.0000000000005406","article-title":"The association of serum magnesium and mortality outcomes in heart failure patients: a systematic review and meta-analysis","volume":"95","author":"Angkananard","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.coph.2020.06.001_bib0235","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s10654-016-0164-4","article-title":"Serum magnesium and risk of new onset heart failure in men: the Kuopio Ischemic Heart Disease Study","volume":"31","author":"Kunutsor","year":"2016","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.coph.2020.06.001_bib0240","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s10654-018-0388-6","article-title":"Serum magnesium and risk of incident heart failure in older men: The British Regional Heart Study","volume":"33","author":"Wannamethee","year":"2018","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.coph.2020.06.001_sbref0245","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000017069","article-title":"Clinical significance of serum magnesium levels in patients with heart failure with preserved ejection fraction","volume":"98","author":"Nishihara","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.coph.2020.06.001_bib0250","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ijcard.2007.11.022","article-title":"Magnesium orotate in severe congestive heart failure (MACH)","volume":"131","author":"Stepura","year":"2009","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.coph.2020.06.001_bib0255","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1053\/j.ackd.2018.02.010","article-title":"Magnesium and cardiovascular disease","volume":"25","author":"Tangvoraphonkchai","year":"2018","journal-title":"Adv Chron Kidney Dis"},{"key":"10.1016\/j.coph.2020.06.001_bib0260","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1007\/s00125-016-4101-6","article-title":"Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials","volume":"59","author":"Tang","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.coph.2020.06.001_bib0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2019.06.007","article-title":"Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: a post hoc analysis of 10 randomized, placebo-controlled trials","author":"Toto","year":"2019","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.coph.2020.06.001_bib0270","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.xkme.2020.01.010","article-title":"SGLT2 inhibitors for treatment of refractory hypomagnesemia: a case report of 3 patients","volume":"3","author":"Ray","year":"2020","journal-title":"Kidney Med"},{"key":"10.1016\/j.coph.2020.06.001_bib0275","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00000441-197203000-00007","article-title":"Effect of angiotensin II on urinary magnesium, calcium, and sodium excretion in normal subjects","volume":"263","author":"Lima","year":"1972","journal-title":"Am J Med Sci"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489220300242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489220300242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:52:28Z","timestamp":1761461548000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489220300242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":55,"alternative-id":["S1471489220300242"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2020.06.001","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolving understanding of cardiovascular protection by SGLT2 inhibitors: focus on renal protection, myocardial effects, uric acid, and magnesium balance","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2020.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}